Nishu Kumar takes part in an MDA at Balia Middle School in Muzaffarpur, district, India.© GSK
We are working with partners to explore potential sites in Benin, India and Malawi to implement DeWorm3 trials.
DeWorm3 invited proposals from endemic countries and partners and after an extensive review of the large number of high-quality proposals by an external panel identified the following partners for DeWorm3 trial sites:
Benin
India
Malawi
The DeWorm3 trials begin in 2017, treatment will continue until 2020 and assessment of post-treatment STH infection and prevalence will continue until 2022.